Featured
The End of the Ozempic Era: Inside Orforglipron, the Daily Weight-Loss Pill That Could Make Injections Obsolete in 2026
Eli Lilly's orforglipron, the first oral GLP-1 weight-loss pill, is awaiting FDA approval in Q2 2026. Here's how it compares to Ozempic, Wegovy, Mounjaro and Zepbound — and what every patient should know before the launch.
News Desk
May 13, 2026